J Biol Chem, Vol. 273, Issue 26, 16146-16154, June 26, 1998
Molecular or Pharmacologic Perturbation of the Link between
Glucose and Lipid Metabolism Is without Effect on
Glucose-stimulated Insulin Secretion
A RE-EVALUATION OF THE LONG-CHAIN ACYL-CoA HYPOTHESIS*
Peter A.
Antinozzi
,
Laura
Segall§,
Marc
Prentki§,
J. Denis
McGarry
, and
Christopher B.
Newgard
¶
From the
Departments of Biochemistry & Internal
Medicine and Gifford Laboratories for Diabetes Research, University of
Texas Southwestern Medical Center, Dallas, Texas 75235 and the
§ Molecular Nutrition Unit, Department of Nutrition,
University of Montreal, Centre de Recherche L.-C. Simard, Institut de
Cancer, Montreal, Quebec H2L 4M1, Canada
 |
ABSTRACT |
The mechanism by which glucose
stimulates insulin secretion from the pancreatic islets of Langerhans
is incompletely understood. It has been suggested that malonyl-CoA
plays a regulatory role by inhibiting fatty acid oxidation and
promoting accumulation of cytosolic long-chain acyl-CoA (LC-CoA). In
the current study, we have re-evaluated this "long-chain acyl-CoA
hypothesis" by using molecular and pharmacologic methods to perturb
lipid metabolism in INS-1 insulinoma cells or rat islets during glucose
stimulation. First, we constructed a recombinant adenovirus containing
the cDNA encoding malonyl-CoA decarboxylase (AdCMV-MCD), an enzyme that decarboxylates malonyl-CoA to acetyl-CoA. INS-1 cells treated with
AdCMV-MCD had dramatically lowered intracellular malonyl CoA levels
compared with AdCMV-
Gal-treated cells at both 3 and 20 mM glucose. Further, at 20 mM glucose,
AdCMV-MCD-treated cells were less effective at suppressing
[1-14C]palmitate oxidation and incorporated 43% less
labeled palmitate and 50% less labeled glucose into cellular lipids
than either AdCMV-
GAL-treated or untreated INS-1 cells. Despite the
large metabolic changes caused by expression of MCD, insulin secretion in response to glucose was unaltered relative to controls. The alternative, pharmacologic approach for perturbing lipid metabolism was
to use triacsin C to inhibit long-chain acyl-CoA synthetase. This agent
caused potent attenuation of palmitate oxidation and glucose or
palmitate incorporation into cellular lipids and also caused a 47%
decrease in total LC-CoA. Despite this, the drug had no effect on
glucose-stimulated insulin secretion in islets or INS-1 cells. We
conclude that significant disruption of the link between glucose and
lipid metabolism does not impair glucose-stimulated insulin secretion
in pancreatic islets or INS-1 cells.
 |
INTRODUCTION |
Glucose is a potent stimulator of insulin secretion from
-cells
of the pancreatic islets of Langerhans. Regulation of insulin secretion
by glucose is thought to be mediated, at least in part, by increases in
the cellular ATP:ADP ratio, resulting in closure of ATP-sensitive
K+ channels, membrane depolarization, and consequent
activation of voltage-dependent Ca2+ channels
(reviewed in Refs. 1 and 2). In recent years the concept that glucose
may also signal via altering lipid metabolism has received significant
experimental support (3-5). Thus, glucose administration to HIT
insulinoma cells results in an increase in malonyl-CoA levels that
precede the rise in insulin secretion. The increase in malonyl-CoA,
acting via its capacity to inhibit the mitochondrial enzyme carnitine
palmitoyltransferase I (6), results in inhibition of fatty acid
oxidation, increased de novo lipid synthesis, and a rise in
diacylglycerol content. These findings led Prentki and colleagues (3,
4) to propose that increases in the levels of cytosolic long-chain
acyl-CoA (LC-CoA)1 esters are
a signal transduction intermediate in glucose-stimulated insulin
secretion, and this idea has come to be known as the "long-chain acyl-CoA hypothesis." Feasible sites at which increased LC-CoA could
influence insulin secretion include conversion to bioactive metabolites
such as diacylglycerol or inositol trisphosphate, contribution to
plasma membrane or secretory granule membrane lipid turnover, or direct
acylation of proteins involved in secretory granule trafficking. While
the proposed mechanisms are reasonable, direct evidence for any of
these actions of lipids on insulin secretion has not been provided to
date.
Other recent studies have demonstrated that the effects of lipids on
-cell function are complex. Lowering of circulating fatty acids via
administration of nicotinic acid (7, 8) or adenovirus-induced
hyperleptinemia (9) completely abrogates glucose-stimulated insulin
secretion, but full secretory function can be restored by provision of
fatty acids to the pancreas of such animals. It has also been
established for some time that fatty acids are acute potentiators of
the glucose-stimulated insulin secretion response (10, 11). In contrast
to these positive acute effects of lipids on islet function, long-term
exposure to hyperlipidemic conditions results in a condition of
"lipotoxicity," wherein lipid overstorage leads to the syndrome of
-cell dysfunction associated with insulin-resistant and diabetic
states, including
-cell hyperplasia, basal hyperinsulinemia, and
loss of glucose responsiveness (12, 13).
In light of the growing emphasis on the role of lipids in
-cell
function, the current study was undertaken to re-investigate the LC-CoA
hypothesis of
-cell signal transduction using novel molecular and
pharmacologic approaches. The goal of the study was to manipulate the
levels of malonyl-CoA and LC-CoA esters during glucose stimulation and
to assess the effect of such maneuvers on insulin secretion. The
molecular approach chosen was to use recombinant adenovirus to express
the enzyme malonyl-CoA decarboxylase, which decarboxylates malonyl-CoA
to acetyl-CoA, thus allowing us to specifically block malonyl-CoA
accumulation during glucose stimulation. The pharmacologic approach was
to use triacsin C, an inhibitor of long-chain acyl-CoA synthetase (14)
to block the conversion of fatty acids to LC-CoA. We demonstrate that
while both approaches have a large impact on lipid metabolism in the
-cell, neither maneuver influences glycolytic flux or
glucose-stimulated insulin secretion.
 |
MATERIALS AND METHODS |
INS-1 Cell Culture and Preparation of Rat Pancreatic
Islets--
INS-1 cells were a gift from Drs. Philippe Halban and
Claes Wollheim (15), and were cultured as described previously (16). Briefly, INS-1 cells (passages 180-260) were grown on 10-cm tissue culture plates (Corning) in RPMI 1640 (Life Technologies, Inc.) media
that contains 11.1 mM glucose, supplemented with 10 mM HEPES, 10% fetal calf serum (Atlanta Biologicals), 2 mM L-glutamine (Life Technologies, Inc.), 100 units/ml penicillin, 10 µg/ml streptomycin (Bio-Whittaker), and 50 µM
-mercaptoethanol. Cultures were incubated at
37 °C in a humidified 95% air, 5%CO2 atmosphere. INS-1
cells were trypsinized (Life Technologies, Inc.) and split (1:2) every 3-4 days for passaging or replated on 12-well tissue culture plates (Corning) for secretion experiments. Floating cell clusters were discarded. Pancreatic islets were prepared from 150-200-g male Sprague-Dawley rats by collagenase digestion and Histopaque density gradient centrifugation as described (17), and used for insulin secretion and metabolic measurements within hours of isolation.
Recombinant Adenovirus Preparation and Use--
A 1.7-kilobase
EcoRI fragment of the malonyl-CoA decarboxylase (MCD)
cDNA lacking its putative N-terminal mitochondrial localization sequence was excised from plasmid pLDC8 (Ref. 18; a generous gift of
Dr. P. E. Kolattukudy, Ohio State University). This fragment was
ligated into EcoRI-digested pAC.CMVpLpA (19) to generate pAC.CMV-MCD. A recombinant adenovirus containing the MCD cDNA (AdCMV-MCD) was then prepared by co-transfection of 293 cells with
pAC.CMV-MCD and JM17 (20) plasmids as described (21). Viral stocks of
AdCMV-MCD and a control virus containing the
-galactosidase gene,
AdCMV-
GAL (22) were purified on a CsCl gradient and titered as
described (21). Twenty-four hours after replating on a 12-well plate,
INS-1 cells were transduced with either virus at a multiplicity of
infection of 1000 plaque forming units/cell. AdCMV-MCD or AdCMV-
GAL viruses were added directly to the RPMI tissue culture media and cells
were exposed to virus for 24 h prior to initiating metabolic studies or insulin measurements of insulin secretion (see below). Cell
viability as assessed by trypan blue exclusion was identical in
AdCMV-MCD, AdCMV-
GAL, and untreated cells after this 24-h treatment
(data not shown).
Insulin Secretion Experiments--
INS-1 cells were grown either
in 12-well dishes or in 10-cm tissue culture plates in the culture
medium described above. Larger plates (10 cm) were required for those
experiments in which malonyl-CoA levels were measured in parallel with
insulin secretion. To study insulin secretion from isolated rat islets,
approximately 50 islets were placed in a 1.5-ml Eppendorf-style tube.
To initiate insulin secretion experiments, the medium was removed,
cells were rinsed in PBS, and then each well was preincubated for
1 h in 4 ml (1 ml for islets) secretion assay buffer (SAB),
containing 3 mM glucose. SAB contains 114 mM
NaCl, 4.7 mM KCl, 1.2 mM
KH2PO4, 1.16 mM MgSO4, 2.5 mM CaCl2, 25 mM
NaHCO3, 20 mM HEPES, and 1% fatty acid-free bovine serum albumin, pH 7.4. SAB was utilized in all subsequent procedures unless otherwise noted. Following this preincubation step,
the medium was aspirated and replaced with 0.5 ml (0.18 ml for islets)
of SAB containing appropriate secretagogues. In some experiments,
insulin secretion from islets or INS-1 cells was studied in the
presence or absence of 10 µM (INS-1 cells) or 50 µM (isolated islets) triacsin C (BioMol), an inhibitor of long-chain acyl-CoA synthetase (14). Medium samples were collected between 30 and 180 min after the initiation of an experiment, centrifuged at 700 × g to remove loose cells, and
subjected to insulin radioimmunoassay (DPC Coat-A-Count), using a rat
insulin standard. The cells remaining in the wells were then washed
once with PBS (Life Technologies, Inc.) and used for the various
measurements described below.
MCD Activity Assay--
MCD activity was assayed by a carnitine
acetyltransferase-linked assay that measures the rate of malonyl-CoA
decarboxylation to acetyl-CoA. The rate of acetyl-CoA production was
monitored by cleavage of its thioester bond with carnitine
acetyltransferase. The thiol group of free CoA was detected with the
colorimetric compound 5,5'-dithiobis(nitrobenzoic acid) (Ellman's
reagent). The reaction mixture (0.25 ml) contained 10 mM
Tris, pH 7.1, 0.2 mM 5,5'-dithiobis(nitrobenzoic acid), 1 mM L-carnitine, 10 mM malonyl-CoA,
and 3 units of carnitine acetyltransferase (Sigma). INS-1 cells were
lysed in 50 mM HEPES, 1% Triton X-100. To initiate the
assay, 500 µg of protein from INS-1 cell homogenates diluted 1:10 in
50 µl of PBS was added to the reaction mixture, and absorbance was
continuously measured at 412 nm for 10 min, over which time the rate of
product accumulation was linear.
Malonyl-CoA Assay--
INS-1 cells were grown to near confluence
in 10-cm plates. The RPMI growth medium was removed and replaced with
SAB containing 3 mM glucose for 1 h. Following this
preincubation, cells were washed once with SAB containing 3 mM glucose and then incubated with SAB containing 3 or 20 mM glucose for 5 or 30 min. Cells were then collected in
1.2 ml of ice-cold 10% trichloroacetic acid and centrifuged at
7,000 × g. The supernatant containing acid soluble
metabolites was collected and washed six times with 0.8 ml of diethyl
ether. Samples were dried in a Speed-Vac and stored at
80 °C prior
to assay of malonyl-CoA levels. For assay, each sample was resuspended
in 0.4 ml of 1 M K2PO4, pH 7.1, and divided into two 0.2-ml aliquots. 100 pmol of malonyl-CoA was added to
one of the two samples, and malonyl-CoA levels were assayed in both
samples according to the method of McGarry and Foster (23), using
purified fatty acid synthetase.
Long-chain Acyl-CoA Assay--
To measure total cellular
long-chain acyl-CoA levels, INS-1 cell extracts were prepared as for
the malonyl-CoA assay, except that cells were incubated in 3 or 20 mM glucose in the presence or absence of triacsin C for
2 h prior to collection of cells in trichloroacetic acid. The
acid-insoluble pellet fraction was washed twice with 1 ml of diethyl
ether and twice with 200 µl of H20. After addition of 250 µl of 10 mM dithiothreitol to the pellet, the pH was
raised to 11.5 with 1 M KOH. Samples were then incubated
for 10 min at 55 °C to hydrolyze the thioester bonds of the
long-chain acyl-CoAs, which are quantitatively recovered in the
trichloroacetic acid-insoluble pellet. Samples were neutralized with 1 M HCl, buffered to a final concentration of 50 mM KPO4, and cleared of debris with a 5000 Mr cut-off spin filter (Millipore). NAD+ and
-ketoglutarate were added to final
concentrations of 500 and 100 µM, respectively. A
fluorescence reading was taken prior to addition of enzyme, and then
again after addition of 20 milliunits of
-ketoglutarate
dehydrogenase (Sigma) to initiate the reaction. Within 10 min, the
reaction reached completion. The change in flourescence was used to
calculate long-chain acyl-CoA concentration in the samples.
-Galactosidase Activity Assays--
-Galactosidase
activity was measured by a colorimetric assay. Cells were homogenized
as for the MCD assays and approximately 500 µg of total protein was
added to a reaction mixture containing 92 mM
NaPO4, 7.5 mM KCl, 0.75 mM
MgSO4, 38 mM
-mercaptoethanol, and 0.67 mg/ml o-nitrophenyl-
-D-galactosidase in a
total volume of 250 µl, and absorbance was monitored for 20 min at
420 nM. Histochemical staining was also performed on plated
cells as described previously (24). At an multiplicity of infection of
1000, approximately 90% of the AdCMV-
GAL-treated cells stained
blue.
Palmitate Oxidation--
INS-1 cells were collected in a
suspension of SAB and equal aliquots were dispensed into center wells
(Kontes) suspended from rubber sleeve stoppers (Fisher). After a 30-min
preincubation with SAB containing 3 mM glucose,
[1-14C]palmitate (NEN Life Science Products Inc.),
glucose, and L-carnitine were added to final concentrations
of 3 or 20 and 0.8 mM, respectively. The center well
containing the reaction mixture was sealed with the rubber sleeve
stopper within a glass scintillation vial. After a 2-h incubation at
37 °C, 100 µl of 7% perchloric acid (Baker) was injected into the
center well and 300 µl of benzethonium hydroxide was injected onto
the bottom of the scintillation vial to capture 14CO2. Following 2 h at 37 °C, the
center well and sleeve stopper were removed, scintillation mixture was
dispensed into the vial, and the palmitate derived
14CO2 was counted.
Glucose and Palmitate Incorporation into Lipids--
INS-1 cells
were subjected to procedures identical to those described for the
insulin secretion studies, with the exception that either
[U-14C] or [3-3H]glucose (NEN Life Science
Products) or [1-14C]palmitate were included as tracers
(0.5 or 5 Ci/mol, respectively). At the conclusion of the 2-h static
incubation, media were collected for insulin assay and 1 ml of
methanol:PBS (2:3) was added to the plated cells. Cells were collected
with gentle pipeting, centrifuged at 700 × g, and
washed once with PBS. 200 µl of 0.2 M NaCl was added to
the cell pellet and the mixture was immediately frozen in liquid
N2. The lipid and aqueous soluble products were separated by the following procedure. To the thawed cell suspension, 750 µl of
CHCl3:methanol (2:1) and 50 µl of 0.1 N KOH
was added and, after vigorous vortexing, the phases were separated by
centrifugation at 2000 × g for 20 min. The top aqueous
layer was removed and the bottom lipid-soluble layer was washed with
200 µl of methanol:water:CHCl3 (48:47:3). 200 µl of
either the aqueous or lipid soluble phase was added to BioSafe2
scintillation mixture and incorporation of radiolabel into lipids was
quantified.
 |
RESULTS |
Effect of MCD Expression on Malonyl-CoA Levels and
Secretion--
Our first strategy for testing the long-chain acyl-CoA
hypothesis was to specifically reduce malonyl-CoA levels during glucose stimulation of INS-1 cells. The enzyme MCD reverses the reaction catalyzed by acetyl-CoA carboxylase by converting malonyl-CoA to
acetyl-CoA. Two sets of experiments were performed with the AdCMV-MCD
virus. In order to measure malonyl-CoA levels, it was necessary to use
large (10 cm) plates of INS-1 cells. Thus, the first set of experiments
measured malonyl-CoA levels and insulin secretion from INS-1 cells
grown in large plates and treated with AdCMV-MCD or the control virus,
AdCMV-
GAL. As shown in Table I, INS-1
cells treated with AdCMV-MCD contained high levels of MCD activity in
crude cellular extracts. In contrast, cells treated with a control
virus (AdCMV-
GAL) contained levels of MCD activity close to the
lower detection limit of the assay, and high levels of
-galactosidase activity. Centrifugation of the crude cellular extracts of AdCMV-MCD-treated cells to yield mitochondria-enriched and
cytosolic fractions (24) revealed that 90% of the MCD was in the
latter fraction, as expected because the expressed enzyme lacks its
N-terminal mitochondrial localization signal.
View this table:
[in this window]
[in a new window]
|
Table I
MCD and -galactosidase enzymatic activity measurements in crude
extracts of untreated INS-1 cells or INS-1 cells treated with a
virus encoding malonyl-CoA decarboxylase (AdCMV-MCD) or
-galactosidase (AdCMV- GAL)
A depicts activity levels for cells studied in 10-cm plates. B depicts
activity levels for cells studied in 12-well dishes. For both panels,
data represent the mean ± S.E. for three independent experiments.
|
|
Fig. 1 shows malonyl-CoA levels in
AdCMV-MCD-treated INS-1 cells relative to AdCMV-
GAL-treated
controls. Two incubation time points were chosen (5 and 30 min), based
on a previous study in which a biphasic profile in malonyl-CoA
accumulation in rat islets perifused with high (25 mM)
glucose was demonstrated (25). As shown in Fig. 1, incubation of
AdCMV-
GAL-treated INS-1 cells in 20 mM glucose for 5 min
caused a 4.2-fold increase in malonyl-CoA levels relative to cells
cultured for the same time period in 3 mM glucose. In
contrast, the increase in malonyl-CoA in response to high glucose in
AdCMV-MCD-treated cells was only 1.8-fold, and the level of malonyl-CoA
attained in control cells incubated at the high glucose concentration
was nearly 3 times that in the AdCMV-MCD-treated cells (24 versus 8.4 pmol/mg of protein). Malonyl-CoA levels were
increased by approximately 60% in AdCMV-
GAL-treated cells incubated
for 30 min at the low glucose concentration compared with cells
incubated for 5 min, and this contributed to a somewhat smaller
(2.4-fold) increment in malonyl-CoA in response to 20 mM
glucose in the 30-min experiments. However, in the 30-min experiments, malonyl-CoA levels in AdCMV-MCD-treated cells incubated at low glucose
were reduced by 70% relative to AdCMV-
GAL-treated cells. Exposure
of the MCD expressing cells to high glucose caused a 2.9-fold increase
in malonyl-CoA levels from this lowered baseline, but the absolute
amount of malonyl-CoA in control cells cultured at high glucose was
still 2.7 times that in AdCMV-MCD-treated cells (22 versus
8.1 pmol/mg protein). Thus, while increases in malonyl-CoA levels in
response to glucose occur in AdCMV-MCD-treated cells, the amount of
malonyl-CoA in AdCMV-MCD-treated cells incubated at 20 mM
glucose was not statistically different from control cells incubated at
3 mM glucose. Finally, the fall in malonyl-CoA level
previously reported in glucose-perifused rat islets at longer time
points (25) was not observed in these static incubation experiments
with INS-1 cells.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Malonyl-CoA levels in AdCMV-MCD and
AdCMV- GAL-treated INS-1 cells. INS-1 cells grown in 10-cm
plates were treated with a virus containing the cDNA encoding
malonyl-CoA decarboxylase (AdCMV-MCD), or a control virus containing
the gene for -galactosidase (AdCMV- GAL). Twenty-four hours after
viral treatment, cells were preincubated in SAB containing 3 mM glucose for 1 h, and then switched to SAB
containing 3 or 20 mM glucose for 5 (left panel)
or 30 (right panel) min. Malonyl-CoA levels were measured in
INS-1 cell extracts as described under "Materials and Methods."
Data represent the mean ± S.E. for six independent experiments.
The asterisk (*) indicates that malonyl-CoA levels were
lower in AdCMV-MCD-treated than in AdCMV- GAL-treated INS-1 cells, at
a level of significance of p < 0.005.
|
|
Despite this block in malonyl-CoA accumulation, MCD expression had no
effect on insulin secretion in response to glucose in INS-1 cells. As
shown in Fig. 2, equal amounts of insulin
were secreted from AdCMV-MCD and AdCMV-
GAL-treated cells at either low (3 mM) or high (20 mM glucose)
concentrations, with the same increase in response to stimulatory
glucose in either group of cells. Note that these static incubation
experiments were carried out for 30 min, in order to be able to
correlate the results with those obtained for malonyl-CoA levels. Thus
the observed increase in insulin secretion in response to stimulatory
glucose of approximately 2-fold is less than the 3-4-fold response
observed by us in static incubation experiments of longer duration
(Ref. 16; see also data in Fig. 5 below). These results indicate that
attainment of a critical threshold of malonyl-CoA concentration, as
defined by the levels reached in control cells incubated at high
glucose, is not a requirement for glucose-stimulated insulin secretion in INS-1 cells.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Insulin secretion from AdCMV-MCD and
AdCMV- GAL-treated INS-1 Cells. Insulin secretion was measured
from cells treated as described in Fig. 1 by radioimmunoassay of media
samples collected after 30 min of incubation at 3 or 20 mM
glucose. Data represent the mean ± S.E. for 12 independent
experiments. Statistical analysis revealed no difference in insulin
secretion between AdCMV-MCD- and AdCMV- GAL-treated INS-1 cells at
either glucose concentration.
|
|
Metabolic Impact of MCD Expression--
By reducing malonyl-CoA
levels, MCD expression is predicted to decrease glucose-induced LC-CoA
accumulation by the two following mechanisms. First, malonyl-CoA is a
key substrate for fatty acid synthase. Depriving fatty acid synthase of
malonyl-CoA availability will decrease de novo lipogenesis
and therefore decrease new LC-CoA biosynthesis. Second, malonyl-CoA is
a potent inhibitor of carnitine palmitoyltransferase I (6). Prevention
of the normal rise in malonyl-CoA levels during glucose stimulation
would therefore be predicted to interfere with LC-CoA accumulation by
favoring fatty acid oxidation relative to de novo synthesis
and esterification. Thus, in the second set of experiments, INS-1 cells
were aliquoted in 12-well plates, treated with AdCMV-MCD, AdCMV-
GAL,
or left untreated, and used for measurement of palmitate oxidation, or glucose or palmitate incorporation into lipid. An independent set of
insulin secretion measurements was also included in this second set of
experiments. As shown in Table I, treatment of cells in 12-well plates
with AdCMV-MCD caused an even more dramatic increase in MCD enzyme
activity in crude extracts than observed in the 10-cm plate experiments
described in Table I.
INS-1 cells, like normal islet
-cells, exhibit an increase in
glycolytic flux and insulin secretion as glucose concentrations are
raised over the physiologic range (15, 16). Previous studies have shown
that when glycolytic flux is high in
-cells, malonyl-CoA levels
increase, carnitine palmitoyltransferase I is inhibited, and fatty acid
oxidation is reduced (3-5). Consistent with this paradigm, switching
of untreated or AdCMV-
GAL-treated INS-1 cells from 3 to 20 mM glucose caused an 80% reduction in
[1-14C]palmitate oxidation (Fig.
3A). In contrast,
AdCMV-MCD-treated cells exhibit only a 59% reduction in palmitate
oxidation in response to the switch from low to high glucose, such that
MCD expressing cells oxidized palmitate at twice the rate of either
control group at 20 mM glucose. Importantly, AdCMV-MCD
expression had no effect on [5-3H]glucose usage or
[1-14C]glucose oxidation at either the low or high
glucose concentration relative to the control groups (data not
shown).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Metabolic impact of malonyl-CoA decarboxylase
expression in INS-1 cells. Panel A,
[1-14C]palmitate oxidation. INS-1 cells were left untreated, or treated with AdCMV-MCD or
AdCMV- GAL viruses for 24 h. After preincubation of cells in SAB
containing 3 mM glucose for 1 h, oxidation was
measured as a function of 14CO2 generation
during a subsequent 2-h incubation with SAB containing radiolabeled
palmitate and either 3 or 20 mM glucose, as described under
"Materials and Methods." Data represent the mean ± S.E. for
three independent experiments, each performed in triplicate. The
asterisk (*) indicates that more palmitate was oxidized in
AdCMV-MCD-treated INS-1 cells than in either control group at 20 mM glucose, at a level of significance of p < 0.001. Panel B, [1-14C]palmitate
incorporation into organically extractable cellular lipids. Cells were
treated identically as described for panel A. After
incubation of cells for 2 h in SAB containing radiolabeled
palmitate and either 3 or 20 mM glucose, cells were
collected and extracted for measurement of incorporation of the fatty
acid into total cellular lipids as described under "Materials and
Methods." Data represent the mean ± S.E. for three independent
experiments. The asterisk (*) indicates that less palmitate
was incorporated into cellular lipids in AdCMV-MCD-treated INS-1 cells
than in either control group at 20 mM glucose, at a level
of significance of p < 0.001. Panel C,
[U-14C]glucose incorporation into organically extractable
cellular lipids. Cells were treated identically as described in
panel A, except that [U-14C]glucose was
substituted for [1-14C]palmitate. After incubation of
cells for 2 h in SAB containing 3 or 20 mM
[U-14C]glucose, cells were collected and extracted for
measurement of incorporation of labeled sugar into total cellular
lipids as described under "Materials and Methods." Data represent
the mean ± S.E. for three independent experiments. The
asterisk (*) indicates that less glucose was incorporated
into cellular lipids in AdCMV-MCD-treated INS-1 cells than in either
control group at 20 mM glucose, at a level of significance
of p < 0.001.
|
|
INS-1 cells incubated in 0.5 mM palmitate, 1% bovine serum
albumin incorporate 2.7 times as much palmitate into complex lipids in
the presence of 20 mM glucose compared with 2 mM glucose (Fig. 3B). This is due to both an
increase in availability of LC-CoA due to decreased palmitate oxidation
and increased glycerol phosphate production via glycolysis. It was
expected that AdCMV-MCD treatment would decrease exogenous palmitate
incorporation into cellular lipids due to the enhanced palmitate
degradation. In fact, AdCMV-MCD treatment reduced
[1-14C]palmitate incorporation into the lipid soluble
phase of INS-1 extracts by 43% compared with untreated or
AdCMV-
GAL-treated cells at 20 mM glucose (Fig. 3B). As
was the case for palmitate oxidation, MCD expression had no effect on
palmitate incorporation into lipids at low glucose.
We also tested the effect of MCD expression on
[U-14C]glucose incorporation into the lipid soluble phase
of INS-1 cell extracts. At 20 mM glucose, MCD expression
reduced glucose incorporation into the lipid phase by 50% compared
with untreated or AdCMV-
GAL-treated controls (Fig. 3C).
However, consistent with the results from the first series of
experiments performed in 10-cm plates and depicted in Fig. 2,
expression of MCD in INS-1 cells in the smaller 12-well plates had no
impact on basal or glucose-stimulated insulin secretion (data not
shown).
In summary, expression of MCD in INS-1 cells impairs normal glucose
suppression of fatty acid oxidation, and causes decreased incorporation
of fatty acids and glucose into cellular lipids, but has no impact on
glucose-stimulated insulin secretion. Because measurements of metabolic
fluxes were carried out in 12-well plates rather than 10-cm dishes, it
was not possible to make parallel measurements of malonyl-CoA levels
for all experiments. However, it should be pointed out that the level
of MCD activity was actually higher in AdCMV-MCD-treated INS-1 cells
grown in 12-well dishes than in 10-cm plates (Table I), suggesting that
malonyl-CoA levels were likely maintained at low levels in both
sets of experiments (see Fig. 1).
Effect of Triacsin C Treatment on Metabolism and Insulin Secretion
in INS-1 Cells--
Triacsin C potently inhibits LC-CoA synthetase, a
microsomal and outer mitochondrial enzyme that condenses long-chain
fatty acid and CoASH by thioester linkage (14). Therefore, an
alternative strategy for testing the LC-CoA hypothesis was to use
triacsin C to block LC-CoA formation from endogenous stores or
exogenous fatty acids, thus preventing their incorporation into mono-,
di-, and triglycerides, as well as phospholipids and acylated proteins. The feasibility of using triacsin C was supported in a study that demonstrated an 80% reduction in [14C]oleate
incorporation into phospholipids and triglycerides in Raji cells (14)
and by our own recent work demonstrating a near-complete block of
radiolabeled glycerol incorporation into cellular lipids in glycerol
kinase expressing INS-1 cells (16).
The metabolic impact of treatment of INS-1 cells with 10 µM triacsin C was monitored by measurement of its effects
on palmitate oxidation and palmitate incorporation into cellular
lipids. Triacsin C treatment caused an 88% reduction in palmitate
oxidation in INS-1 cells incubated at 3 mM glucose relative
to control cells incubated at the same glucose concentration in the
absence of the drug (Fig. 4A),
while palmitate oxidation was essentially unmeasurable at 20 mM glucose in triacsin C-treated cells. Thus, unlike the
case with MCD expression, the block of palmitate oxidation by triacsin
C was evident at both low and high glucose concentrations. Similarly,
triacsin C treatment reduced [1-14C]palmitate
incorporation into cellular lipid by 62% at 20 mM glucose
and by 50% at 3 mM glucose (Fig. 4B). As was
the case for AdCMV-MCD-treated INS-1 cells, triacsin C treatment of
INS-1 cells had no effect on [5-3H]glucose usage (data
not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of triacsin C on palmitate metabolism
in INS-1 cells. Panel A, [1-14C]palmitate
oxidation. INS-1 cells were preincubated in SAB containing 3 mM glucose, in the presence or absence of 10 µM triacsin C, for 2 h, and oxidation was measured
as a function of 14CO2 generation during a
subsequent 2-h incubation with SAB containing radiolabeled palmitate
and either 3 or 20 mM glucose, in the presence or absence
of 10 µM triacsin C. Data represent the mean ± S.E.
for four independent experiments. The asterisk (*) indicates
that less palmitate was oxidized in triacsin C-treated INS-1 cells than
in untreated control cells at either glucose concentration, at a level
of significance of p < 0.001. Panel B,
[1-14C]palmitate incorporation into organically
extractable cellular lipids. Cells were treated identically as
described for panel A. After incubation of cells for 2 h in SAB containing radiolabeled palmitate and either 3 or 20 mM glucose, with or without 10 µM triacsin C,
cells were collected and extracted for measurement of incorporation of
the fatty acid into total cellular lipids as described under
"Materials and Methods." Data represent the mean ± S.E. for
four independent experiments. The asterisk (*) indicates
that less palmitate was incorporated into cellular lipids in triacsin
C-treated INS-1 cells than in untreated control cells at either glucose
concentration, at a level of significance of p < 0.001.
|
|
The foregoing experiments, while demonstrating potent triacsin
C-mediated inhibition of metabolism of exogenously added fatty acids,
leave open the possibility that the pre-existing intracellular LC-CoA
pool may enter esterification pathways during glucose stimulation, thereby contributing in some way to regulation of insulin secretion. To
test this we monitored [3-3H]glucose incorporation into
organically extractable lipids in INS-1 cells incubated in the presence
and absence of triacsin C. These experiments were performed in the
absence of exogenous fatty acids. Thus, incorporation of radiolabeled
glucose into lipids in the presence of triacsin C should reflect
primarily the esterification of pre-formed LC-CoA with radiolabeled
glycerol phosphate derived from glycolysis. As shown in Fig.
5A, incorporation of
[3-3H]glucose into lipids increases in proportion to the
glucose concentration over the range of 3 to 10 mM in INS-1
cells not exposed to triacsin C, with a maximal value of 12 nmol of
glucose incorporated/mg of protein/h measured at 10 mM
glucose. In contrast, cells exposed to triacsin C incorporate only half
as much labeled glucose into lipids at basal glucose (3 mM)
as control cells. Glucose incorporation is increased in triacsin
C-treated cells as glucose is raised to 4-5 mM, but then
fails to continue to rise at higher concentrations of the sugar, with
maximal values of only 4 nmol of glucose incorporated/mg of protein/h
at glucose concentrations of 5 mM or greater.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of triacsin C on glucose incorporation
into lipids and glucose-stimulated insulin secretion. Panel
A, [3-3H]glucose incorporation into organically
extractable cellular lipids. INS-1 cells were preincubated in SAB
containing 2 mM glucose in the presence or absence of 10 µM triacsin C for 2 h. Cells were then switched to
SAB containing various concentrations of [3-3H]glucose
with or without 10 µM triacsin C, and after a further 2-h
incubation, cells were collected and extracted for measurement of
incorporation of labeled sugar into total cellular lipids as described
under "Materials and Methods." Data represent the mean ± S.E.
for three independent experiments per glucose concentration. The
asterisks (*) indicate that less glucose was incorporated
into cellular lipids in triacsin C-treated cells than in controls at
the indicated glucose concentrations. Panel B, insulin
secretion. Media samples were collected from the cells described in
panel A and subjected to insulin radioimmunoassay. Data
represent the mean ± S.E. for three independent
experiments.
|
|
Insulin secretion was measured in parallel with the metabolic
measurements reported in Fig. 5A. As shown in Fig.
5B, insulin secretion was increased in direct proportion to
glucose concentration in both triacsin C-treated and control INS-1
cells. Insulin secretion rose from approximately 50 microunits/mg of
protein/h at 3 mM glucose to 80 microunits/mg of protein/h
at 5 mM glucose, a range over which glucose incorporation
into lipid was increased in both groups of cells, but then continued to
rise from 80 microunits/mg of protein/h at 5 mM glucose to
160 microunits/mg of protein/h as glucose was raised to 10 mM in both groups, despite a complete block in further
glucose incorporation into lipids in the triacsin C-treated cells. No
further increases in insulin secretion or labeled glucose incorporation
into lipids were observed at 20 mM glucose compared with 10 mM glucose (data not shown). We conclude from these studies
that triacsin C effectively limits the incorporation of radiolabeled
glucose or palmitate into cellular lipids, and that during blockade of
LC-CoA synthetase, there is no large pool of preformed LC-CoA that
participates in esterification pathways. Furthermore, interruption of
LC-CoA synthesis is without effect on glucose-stimulated insulin
secretion.
In their studies in which the LC-CoA hypothesis was introduced, Prentki
and co-workers (4) actually found a decrease in total cellular LC-CoA
content during glucose stimulation of hamster insulinoma (HIT) cells.
This finding was discounted, however, because the huge pool of
mitochondrial LC-CoA in whole cell extracts is likely to obscure any
changes in the cytoplasmic pool. Nevertheless, we wondered whether
triacsin C, by virtue of its blockade of de novo synthesis
of LC-CoA would have a measurable impact on total cellular LC-CoA
levels. Similar to previous observations, stimulation of INS-1 cells
with 20 mM glucose did not increase total LC-CoA relative
to cells incubated at 3 mM glucose (Fig.
6). However, addition of triacsin C for
the 2-h incubation period lowered total LC-CoA levels by 45% at either
glucose concentration. Thus, triacsin C markedly reduces total cellular
LC-CoA levels, and this decrease probably impacts both mitochondrial
and cytosolic pools.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of triacsin C on total cellular LC-CoA
levels. INS-1 cells were preincubated in SAB, 3 mM
glucose, either lacking or containing 10 µM triacsin C
for 30 min. This media was removed and replaced with SAB containing 3 or 20 mM glucose in the presence or absence of 10 µM triacsin C for 2 h. Cells were harvested and
assayed for total LC-CoA as described under "Materials and
Methods." Data represent the mean ± S.E. for three independent
groups of cells per condition. The asterisk (*) indicates a
lower LC-CoA level in triacsin C-treated cells, with significance of
p 0.005.
|
|
Effect of Triacsin C on Glucose-stimulated Insulin Secretion from
Freshly Isolated Rat Islets--
The LC-CoA hypothesis was originally
conceived from data collected from studies on insulinoma cell lines (3,
4). Thus, the work described herein on INS-1 cells, a well
differentiated
-cell line, would appear to represent a valid test of
the hypothesis. It remains possible, however, that perturbations in
lipid metabolism could have effects on regulation of insulin secretion
in normal islets that were not observed in our INS-1 cell experiments.
To deal with this concern, we investigated the impact of triacsin C
treatment on freshly isolated rat islets of Langerhans. We found that
in order to observe potent perturbation of lipid metabolism in intact
islets, a higher concentration of triacsin C was required than used in
the INS-1 cells experiments (50 versus 10 µM,
respectively). As was the case for INS-1 cells, triacsin C treatment or
fresh rat islets resulted in a significant reduction of palmitate
oxidation at 3 mM glucose (Fig.
7, inset), verifying that the
drug has a similar metabolic impact in the two cell preparations. The
freshly isolated rat islets exhibited a 4-fold increase in insulin
secretion in response to a change from 3 to 20 mM glucose,
but once again, triacsin C had no inhibitory effect on this
response (Fig. 7). These data verify the lack of impact of large
perturbations of lipid metabolism on glucose-stimulated insulin
secretion in two independent in vitro models.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of triacsin C on insulin secretion
from freshly isolated rat islets. Freshly isolated rat islets were
incubated in SAB supplemented with 3 or 20 mM glucose, with
or without 50 µM triacsin C, for 2 h, and media
samples were collected for insulin radioimmunoassay. Data represent the
mean ± S.E. for four independent experiments. Statistical
analysis revealed no difference in insulin secretion between triacsin C
and untreated islets at either glucose concentration. The
inset shows the effect of 50 µM triacsin C on
[1-14C]palmitate oxidation in freshly isolated rat islets
incubated at 3 mM glucose (data represent the mean ± S.E. for three independent determinations per condition).
|
|
 |
DISCUSSION |
In this study we have applied molecular (MCD expression) and
pharmacologic (triacsin C treatment) strategies for attenuating glucose-induced alterations in lipid metabolism in insulin-secreting cells. Suprisingly, neither approach impaired glycolysis or affected glucose-stimulated insulin secretion in INS-1 cells, and the lack of
impact of triacsin C on regulation of insulin secretion was also
confirmed in freshly isolated rat islets. These results suggest that
reassessment of the long-chain acyl-CoA hypothesis for stimulus secretion coupling in islet
-cells is in order. Two important observations that led to development of the hypothesis were: 1) increasing glycolytic flux in
-cells by increasing the extracellular glucose concentration led to an increase in malonyl-CoA levels proportional to insulin secretion (3, 4), and 2) glucose-mediated alterations in malonyl-CoA levels were linked to changes in lipid metabolism and the cytosolic LC-CoA pool, which in turn was suggested to trigger insulin secretion by an undefined mechanism (3-5). In what
follows, these two critical observations are re-evaluated in the
context of the data obtained in the current study.
First, increasing glycolytic flux in
-cells by increasing the
extracellular glucose concentration leads to an increase in malonyl-CoA
levels that is proportional to insulin secretion. Our findings are in
agreement with this cornerstone observation of the LC-CoA hypothesis,
but only in control INS-1 cells. We find that malonyl-CoA levels are
increased in response to a change in glucose concentration from 3 to 20 mM at both 5 and 30 min in control INS-1 cells, the same
range over which glucose stimulated-insulin secretion. However,
expression of MCD in INS-1 cells sharply attenuates the rise in
malonyl-CoA levels in response to stimulatory glucose at the 5-min time
point. At 30 min, MCD expression lowers basal malonyl-CoA levels
substantially, but allows an increase in the intermediate in response
to glucose. However, at both 5 and 30 min, the levels of malonyl-CoA
achieved in MCD expressing cells exposed to 20 mM glucose
are well below the levels in control cells incubated at 20 mM glucose and are in fact not statistically different than
the levels in control cells incubated at 3 mM glucose. These data indicate that the high levels of malonyl-CoA achieved in
glucose-stimulated control INS-1 cells do not define a critical threshold of the intermediate that must be achieved in order for insulin secretion to be activated. However, we cannot as yet formally exclude the unlikely possibility that the increment in malonyl-CoA that
remains in MCD expressing cells at the 30-min time point is involved in
stimulus/secretion coupling.
Second, glucose-mediated alterations in malonyl-CoA levels are linked
to changes in lipid metabolism and an increase in the cytosolic LC-CoA
pool that regulate insulin secretion. Again, we were able to confirm
the correlative linkage between lipid metabolism and insulin secretion
(3-5), but only in INS-1 cells not engineered for MCD expression or
treated with triacsin C. In such control cells, raising glucose from 3 to 20 mM results in a profound inhibition of fatty acid
oxidation, with concomitant and potent activation of incorporation of
radiolabeled glucose and palmitate into organically extractable
cellular lipids. It is assumed that the increased incorporation of
glucose or palmitate into lipids reflects accumulation of cytosolic
LC-CoA, the necessary intermediate for synthesis of end products such
as phospholipids and triglycerides. Interestingly, previous
measurements of LC-CoA during glucose stimulation of a hamster
insulinoma cell line (HIT) showed a decrease in the total LC-CoA pool
(3). It was suggested that the total LC-CoA pool largely represents
material sequestered in the mitochondria, and is an inaccurate measure
of changes in the more relevant cytoplasmic pool (3). This represents a
technical limitation for evaluating the relationship between
cytoplasmic LC-CoA and insulin secretion. However, in the current
study, we have utilized triacsin C as a direct inhibitor of long-chain
acyl-CoA synthetase, the enzyme responsible for LC-CoA synthesis. We
find that this reagent has its anticipated effects of sharply
suppressing fatty acid oxidation and esterification in both INS-1 cells
and freshly isolated rat islets, but does not influence
glucose-stimulated insulin secretion. Importantly, triacsin C also
causes a 45% decrease in total LC-CoA levels in INS-1 cells incubated
at either low or high glucose concentrations. Similarly, expression of
MCD in INS-1 cells significantly attenuates glucose-induced suppression of fatty acid oxidation while decreasing glucose and palmitate incorporation into cellular lipids with no effect on regulation of
insulin secretion. Because these two completely independent methods
produced similar results, we conclude that there is no direct
correlation between the extent to which lipids are directed toward
oxidative or esterification pathways and insulin secretion. While we
have not directly measured the cytosolic LC-CoA pool, to the extent
that the fall in total LC-CoA in response to triacsin C is reflective
of this fraction, our data also argue that a rise in LC-CoA is not a
critical event in glucose-stimulated insulin secretion. This conclusion
is also applicable to other carbohydrate secretagogues, since we have
recently shown that blockade of glycerol incorporation into cellular
lipids with triacsin C in glycerol kinase-expressing INS-1 cells has no
effect on glycerol-stimulated insulin secretion (16).
Note that in a recent study in fibroblasts, triacsin C was shown to be
almost completely effective in blocking triglyceride and phospholipid
synthesis from glycerol, while incorporation of oleate or arachidonate
into phospholipids was less impaired (26). Similarly, using thin layer
chromatography analysis of INS-1 cell extracts, we have observed that
triacsin C inhibits conversion of [1-14C]palmitate into
triglycerides by more than 90%, while incorporation of the same
substrate into phospholipids is reduced by 50% (data not shown). Thus,
while the effects of MCD expression or triacsin C treatment on lipid
fluxes in our studies were large, they were not complete, and it
remains possible that a small residual flux of substrate into specific
esterification or biosynthetic pathways is required for maintenance of
glucose responsiveness. It could be envisaged, for example, that a
lesser efficiency of triacsin C for blockade of phospholipid
biosynthesis could allow maintenance of a critical pool of this
substrate for phospholipase A2-mediated hydrolysis and
release of potential second messengers such as arachadonic acid (27).
Furthermore, our results are not simply reconciled with earlier
experiments in which a presumed block of malonyl-CoA synthesis with the
citrate lyase inhibitor, hydroxycitrate, in the perfused rat pancreas
was found to inhibit glucose-stimulated insulin secretion, an effect
that was reversible by palmitate addition (5). It should be noted,
however, that studies by other investigators failed to demonstrate an
effect of hydroxycitrate on isolated rat islets (28), and in
confirmation of this finding, no effect of the drug on insulin
secretion was observed in fresh rat islets or INS-1 cells by us (data
not shown). Also, addition of the
-oxidation inhibitor, etomoxir, to
the perfused pancreas preparation potentiates insulin secretion, but
only at concentrations 10 times higher than required to inhibit
oxidation, suggesting that the effect of this reagent on insulin
secretion may be via its structural similarity to saturated fatty
acids, which are known potentiators of insulin release (5). We can only
speculate that the intact pancreas has a unique susceptibility to
hydroxycitrate compared with isolated islets or INS-1 cells, or that
this reagent has effects at sites other than inhibition of citrate
lyase in the perfused pancreas preparation. Perhaps culturing isolated islets or cell lines in rich media containing essential lipids from the
fetal calf serum is sufficient to overcome hydroxycitrate-mediated inhibition of lipogenesis. Additionally, isolated islets and
-cell lines may have a greater storage capacity for lipids than the intact
pancreas, which would make the pancreas more susceptible to lipogenic
inhibitors. Thus, while we feel that our major conclusion that large
alterations in lipid metabolism are not linked to perturbations in
glucose-regulated insulin secretion is correct for freshly isolated rat
islets and INS-1 cells, it remains possible that islets in
situ are sensitive to regulation by such a mechanism.
It has, in fact, recently been shown that complete depletion of lipid
stores in islets blocks normal responsiveness to glucose and other
secretagogues. Thus, animals treated with nicotinic acid to lower
circulating free fatty acid exhibit no increase in insulin secretion in
response to a glucose challenge (7, 8). Similarly, islets in the
perfused pancreas of animals rendered hyperleptinemic for a period of 1 week are completely devoid of triglyceride and fail to respond to
glucose or arginine as a secretagogue, while animals pair-fed to the
lower rate of food intake of hyperleptinemic animals retain normal
islet function and some residual triglyceride (9). Insulin secretion in
response to glucose can be rapidly restored by lipid infusion into
nicotinic acid-treated animals (7, 8), or by inclusion of fatty acids
during perfusion of pancreata from fasted or hyperleptinemic animals
(7-9). These data argue that lipids must be present, at least at some
minimal level, in order for islet
-cells to function normally.
In light of all of these results, we suggest the following modification
of the long-chain acyl-CoA hypothesis. Our work shows that large
impairment in the normal link between glucose and lipid metabolism in
-cells is tolerated with no impact on glucose-stimulated insulin
secretion, as long as glycolytic flux is not perturbed. This allows us
to narrow the search for metabolic pathways and coupling factors
involved in acute glucose-stimulated insulin secretion. With the
apparent elimination of changes in malonyl-CoA levels and
attendant alterations in lipid metabolism, the most likely candidates
now include a glycolytic signal, oxidative events, or anaplerosis (1,
2, 29). The primary signal may include the well recognized
glucose-driven increase in ATP:ADP ratio, leading to inhibition of
ATP-sensitive K+ channels and influx of extracellular
Ca2+ (1, 2).
Our experiments were designed to evaluate the effect of acute
perturbation of the link between glucose and lipid metabolism. The
abrogation of glucose-stimulated insulin secretion by more long term
maneuvers such as nicotinic acid administration or adenovirus-induced hyperleptinemia (7-9) may be explained by lipid depletion and the
resultant absence of essential modulators of secretory granule trafficking and/or exocytosis. Examples of distal sites at which lipids
may be acting include generation of signaling molecules such as
diacylglycerol or inositol trisphosphate, or via contribution to
secretory granule or plasma membrane turnover (3-5). That lipids are
acting at a distal rather than a proximal site is supported by the
finding that lipid-depleted islets not only fail to respond to glucose
but also show no response to arginine, leucine, or the sulfonylurea,
glibenclamide (9, 30). Arginine is thought to exert its secretory
effects by directly affecting membrane polarization, while
sulfonylureas are believed to bring about the same effect by inhibiting
ATP-sensitive K+ channel activity. Thus, both agents act
distal to any anticipated early metabolic signal. Yet with all
secretagogues tested to date, the attenuated insulin response in
lipid-depleted islets is restored to normal by inclusion of fatty acids
in the perfusate (7-9, 30). The mechanism by which fatty acids
exert these important modulatory effects on insulin secretion
remain to be established.
Finally, it should be emphasized that the data do not discount the
possibility that the malonyl-CoA/carnitine palmitoyltransferase I
metabolic signaling network may play important roles in long-term processes related to insulin secretion, i.e.
-cell
growth, apoptosis, regulation of important metabolic genes, and effects
related to chronic exposure of
-cells to high concentrations of
fatty acids (i.e. changes in glucose sensitivity,
"lipotoxicity") (2, 12, 31, 32). The molecular and pharmacologic
tools described in this paper should be useful for future investigation
of these issues.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Roger Unger and Dr. Chris Rhodes
for helpful discussion and critical review of the manuscript and Donna
Lehman for expert technical assistance.
 |
Note Added in Proof |
After submission of this paper we became
aware of an article by Zhang and Kim in which stable expression of
acetyl CoA carboxylase (ACC) antisense RNA in INS-1 cells was reported
(33). In cells expressing the ACC antisense construct, a 40% reduction
in ACC enzymatic activity correlated with a similar decrease in
glucose-stimulated insulin secretion and malonyl CoA levels and an
approximate doubling of the rate of fatty acid oxidation. One potential
explanation for these findings is that stable suppression of ACC
activity, as opposed to transient expression of MCD or short term
treatment with triacsin C, may lead to a depletion of the cellular
lipid stores, similar to what is observed in animals treated with
nicotinic acid or infused with an adenovirus containing the leptin cDNA (7-9). This possibility could be evaluated in the future by
examination of the effects of MCD expression for time periods longer
than those used in the current study.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK 46492-05 (to C. B. N.) and DK 18573 (to J. D. M.), grants from the National Institutes of Health/Juvenile
Diabetes Foundation International Research Program (to C. B. N. and J. D. M.), and the Medical Research Council of Canada,
the Canadian Diabetes Association, and the Juvenile Diabetes Foundation
International (to M. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Gifford
Laboratories for Diabetes Research, Rm. Y8.212, University of Texas
Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235. Tel.: 214-648-2930; Fax: 214-648-9191; E-mail:
Newgard{at}utsw.swmed.edu.
1
The abbreviations used are: LC-CoA, long-chain
acyl-coenzyme A; MCD, malonyl-CoA decarboxylase; PBS,
phosphate-buffered saline;
-gal,
-galactosidase; SAB, secretion
assay buffer; ACC, acetyl CoA carboxylase.
 |
REFERENCES |
-
Meglasson, M. D.,
and Matschinsky, F. M.
(1986)
Diabetes Metab. Rev.
2,
163-214[Medline]
[Order article via Infotrieve]
-
Newgard, C. B.,
and McGarry, J. D.
(1995)
Annu. Rev. Biochem.
64,
689-719[CrossRef][Medline]
[Order article via Infotrieve]
-
Corkey, B. E.,
Glennon, M. C.,
Chen, K. S.,
Deeney, J. T.,
Matschinsky, F. M.,
and Prentki, M.
(1989)
J. Biol. Chem.
264,
21608-21612[Abstract/Free Full Text]
-
Prentki, M.,
Vischer, S.,
Glennon, M.,
Regazzi, R.,
Deeney, J.,
and Corkey, B. E.
(1992)
J. Biol. Chem.
267,
5802-5810[Abstract/Free Full Text]
-
Chen, S.,
Ogawa, A.,
Ohneda, M.,
Unger, R. H.,
Foster, D. W.,
and McGarry, J. D.
(1994)
Diabetes
43,
878-883[Abstract]
-
McGarry, J. D.,
Woeltje, K. F.,
Kuwajima, M.,
and Foster, D. W.
(1989)
Diabetes Metab. Rev.
5,
271-284[Medline]
[Order article via Infotrieve]
-
Stein, D. T.,
Esser, V.,
Stevenson, B. E.,
Lane, K. E.,
Whiteside, J. H.,
Daniels, M. B.,
Chen, S.,
and McGarry, J. D.
(1996)
J. Clin. Invest.
97,
2728-2735[Medline]
[Order article via Infotrieve]
-
Stein, D. T.,
Stevenson, B. E.,
Chester, M. W.,
Basit, M.,
Daniels, M. B.,
Turley, S. D.,
and McGarry, J. D.
(1997)
J. Clin. Invest.
100,
398-403[Medline]
[Order article via Infotrieve]
-
Koyama, K.,
Chen, G.,
Wang, M-Y.,
Lee, Y.,
Shimabukuro, M.,
Newgard, C. B.,
and Unger, R. H.
(1997)
Diabetes
46,
1276-1280[Abstract]
-
Tamarit-Rodriguez, J.,
Vara, E.,
and Tamarit, J.
(1984)
Biochem. J.
221,
317-324[Medline]
[Order article via Infotrieve]
-
Bedoya, F. J.,
Ramirez, R.,
Arilla, E.,
and Goberna, R.
(1984)
Diabetes
33,
858-863[Abstract]
-
Unger, R. H.
(1995)
Diabetes
44,
863-870[Abstract]
-
Zhou, Y-P.,
and Grill, V. E.
(1995)
J. Clin. Endocrinol. & Metab.
80,
1584-1590[Abstract/Free Full Text]
-
Tomoda, H.,
Igarashi, K.,
and Omura, S.
(1987)
Biochim. Biophys. Acta
921,
595-598[Medline]
[Order article via Infotrieve]
-
Asfari, M.,
Janjic, D.,
Meda, P.,
Li, G.,
Halban, P. A.,
and Wollheim, C. B.
(1991)
Endocrinology
130,
167-178[Abstract]
-
Noel, R. J.,
Antinozzi, P. A.,
McGarry, J. D.,
and Newgard, C. B.
(1997)
J. Biol. Chem.
272,
18621-18627[Abstract/Free Full Text]
-
Alarcon, C.,
Lincoln, B.,
and Rhodes, C. J.
(1993)
J. Biol. Chem.
268,
4276-4280[Abstract/Free Full Text]
-
Jang, S-H.,
Cheesbrough, T. M.,
and Kolattukudy, P. E.
(1989)
J. Biol. Chem.
264,
3500-3505[Abstract/Free Full Text]
-
Gomez-Foix, A. M.,
Coats, W. S.,
Baque, S.,
Alam, T.,
Gerard, R. D.,
and Newgard, C. B.
(1992)
J. Biol. Chem.
267,
25129-25134[Abstract/Free Full Text]
-
McCrory, W. J.,
Bautista, D. S.,
and Graham, F. L.
(1988)
Virology
163,
614-617[CrossRef][Medline]
[Order article via Infotrieve]
-
Becker, T. C.,
Noel, R. J.,
Coats, W. S.,
Gomez-Foix, A. M.,
Alam, T.,
and Newgard, C. B.
(1994)
Methods Cell Biol.
43,
162-189
-
Herz, J.,
and Gerard, R. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2812-2816[Abstract/Free Full Text]
-
McGarry, J. D.,
and Foster, D. W.
(1979)
J. Biol. Chem.
254,
8163-8168[Free Full Text]
-
Becker, T. C.,
BeltrandelRio, H.,
Noel, R. J.,
Johnson, J. H.,
and Newgard, C. B.
(1994)
J. Biol. Chem.
269,
21234-21238[Abstract/Free Full Text]
-
Liang, Y.,
and Matschinsky, F. M.
(1991)
Diabetes
40,
327-333[Abstract]
-
Igal, R. A.,
Wang, P.,
and Coleman, R. A.
(1997)
Biochem. J.
324,
529-534
-
Turk, J.,
Wolf, B. A.,
and McDaniel, M. L.
(1987)
Prog. Lipid Res.
26,
125-181[CrossRef][Medline]
[Order article via Infotrieve]
-
Sener, A.,
and Malaisse, W. J.
(1991)
Biochimie
73,
1287-1290[Medline]
[Order article via Infotrieve]
-
Prentki, M.
(1996)
Eur. J. Endocrinol.
134,
272-286[CrossRef][Medline]
[Order article via Infotrieve]
-
Dobbins, R. L., Chester, M. W., Stevenson, B. E.,
Daniels, M. B., Stein, D. T., and McGarry, J. D. (1997)
J. Clin. Invest., in press
-
Prentki, M.,
and Corkey, B. E.
(1996)
Diabetes
45,
273-283[Abstract]
-
Hosokawa, H.,
Corkey, B. E.,
and Leahy, J. L.
(1997)
Diabetologia
40,
392-397[CrossRef][Medline]
[Order article via Infotrieve]
-
Zhang, S.,
and Kim, K.-H.
(1998)
Cell Signal.
10,
35-42[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
